Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 901–1,000 of 1,026
Sudden Cardiac Death in Ischemic Heart Disease
Gräni, C., Benz, D. C., Gupta, S., Windecker, S., & Kwong, R. Y. K. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.10.021 · Cited by 61
Vaduganathan, M., Jhund, P. S., Claggett, B. L., Packer, M., Widimsky, J., Jr., Seferovic, P. M., Rizkala, A. R., Lefkowitz, M. P., Shi, V. C., McMurray, J. J. V., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa184 · Cited by 51
Self-citationCastrichini, M., Manca, P., Nuzzi, V., Barbati, G., Luca, A. D., Korcova, R., Stolfo, D., Lenarda, A. D., Merlo, M., & Sinagra, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040906 · Cited by 59
“The findings of the Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with an Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM HF) trial have been revolutionary for HFrEF management [7].”
BackgroundYan, Y., Liu, B., Du, J. C., Wang, J., Jing, X., Liu, Y., Deng, S., Du, J., & She, Q. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13313 · Cited by 50
“93) in PARADIGM-HF.(6) These findings are also confirmed by real-world studies.”
BackgroundInfluentialButt, J. H., Docherty, K. F., Petrie, M. C., Schou, M., Kosiborod, M., O’Meara, E., Katova, T., Ljungman, C. E. A., Díez, M., Ogunniyi, M. O., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0379 · Cited by 61
Self-citationAngiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
Sutanto, H., Dobrev, D., & Heijman, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168994 · Cited by 52
“Patient Characteristics Number of Patients Arrhythmic Outcome(s) Effect REF Atrial Arrhythmias SAVETHERHYTHM (HFrEF patients with CRT-D or ICD) Preliminary: 60 patients with sacubitril/valsartan followed over 12 months Mean number of sustained atrial tachycardia (AT) or AF episodes per month, total AT/AF burden, mean…”
BackgroundResultInfluentialHeart failure in adults with congenital heart disease
Brida, M., Lovrić, D., Griselli, M., Gil, F., & Gatzoulis, M. Α. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.018 · Cited by 50
Neprilysin Inhibition — A Novel Therapy for Heart Failure
Jessup, M. L. (2014) · New England Journal of Medicine · doi:10.1056/nejme1409898 · Cited by 48
Peng, S., Lu, X., Qi, Y., Li, J., Xu, J., Yuan, T., Wu, X., Ding, Y., Li, W., Zhou, G., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9815039 · Cited by 49
“LCZ696 is an angiotensin-receptor-neprilysin inhibitor (ARNI) consisting of the neprilysin inhibitor sacubitril (AHU377) and angiotensin-receptor blocker (ARB) valsartan [4].”
BackgroundDeclining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
Leyva, F., Israel, C. W., & Singh, J. P. (2023) · Circulation · doi:10.1161/circulationaha.122.062159 · Cited by 53
Heart Failure in Patients with Chronic Kidney Disease
Xanthopoulos, A. V., Papamichail, A., Briasoulis, Α., Loritis, K., Bourazana, A., Magouliotis, D. E., Sarafidis, P. A., Stefanidis, I., Skoularigis, J. S., & Triposkiadis, F. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186105 · Cited by 68
“…with HF, as demonstrated in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) [82] and the Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction (PARAGON-HF) [83] trials.”
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Kario, K., Tamaki, Y., Okino, N., Gotou, H., Zhu, M., & Zhang, J. Y. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12667 · Cited by 53
“In patients with heart failure in the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With AngiotensinConverting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF), LCZ696 was superior in reducing the risk of CV death and HF hospitalization c…”
BackgroundSoluble Neprilysin does not Correlate with Outcome in Heart Failure with Preserved Ejection Fraction
Goliasch, G., Pávó, N., Zotter‐Tufaro, C., Kammerlander, A. A., Duca, F., Mascherbauer, J., & Bonderman, D. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.435 · Cited by 48
Sacubitril/Valsartan (LCZ696) in Heart Failure
Khder, Y., Shi, V. C., McMurray, J. J. V., & Lefkowitz, M. P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_77 · Cited by 54
Self-citationThe Role for Cardiovascular Remodeling in Cardiovascular Outcomes
Sekaran, N. K., Crowley, A. L., de Souza, F. R., Resende, E. S., & Rao, S. V. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0656-z · Cited by 46
Treatment of Heart Failure with Preserved Ejection Fraction
Ilieșiu, A. M., & Hodorogea, A. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_149 · Cited by 59
Ichiki, T., Dzhoyashvili, N. A., & Burnett, J. C. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.002 · Cited by 50
Kasahara, S., Sakata, Y., Nochioka, K., Miura, M., Abe, R., Sato, M., Aoyanagi, H., Fujihashi, T., Yamanaka, S., Shiroto, T., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.069 · Cited by 51
Bayard, G., Costa, A. D., Pierrard, R., Romeyer-Bouchard, C., Guichard, J.-B., & Isaaz, K. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100418 · Cited by 55
Boutagy, N. E., Fehér, A., Pfau, D. J., Liu, Z., Guerrera, N. M., Freeburg, L., Womack, S. J., Hoenes, A., Zeiss, C. J., Young, L. H., et al. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.09.007 · Cited by 47
“Sacubitril/valsartan (Sac/Val) is a first-inclass clinically available angiotensin receptorneprilysin inhibitor that reduced cardiovascular events in patients with heart failure (18).”
BackgroundHulot, J., Trochu, J., Donal, E., Galinier, M., Logeart, D., de Groote, P., & Juillière, Y. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1937121 · Cited by 54
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 52
“A significant reduction in the primary composite endpoint (death from CV causes or first hospitalisation for worsening HF, death from CV causes, hospitalisation for HF and death from any cause) was observed [36].”
BackgroundReverse Cardiac Remodeling and ARNI Therapy
Abboud, A., & Januzzi, J. L. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00501-6 · Cited by 55
Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial
Herrmann, J. J., Brunner-La Rocca, H.-P., Baltussen, L. E. H. J. M., Beckers-Wesche, F., Bekkers, S. C. A. M., Bellersen, L., van Eck, J. W. M., Hassing, H. C., Jaarsma, T., Linssen, G. C. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03628-4 · Cited by 46
NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure
Schmitt, W., Ruehs, H., Burghaus, R., Diedrich, C., Duwal, S., Eißing, T., Garmann, D., Meyer, M. C., Ploeger, B. A., & Lippert, J. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2222 · Cited by 53
Belali, O. M., Ahmed, M. M., Mohany, M., Belali, T. M., Alotaibi, M. M., Alhoshani, A., & Al-Rejaie, S. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031288 · Cited by 54
“Clinical studies have reported that LCZ696 is superior to enalapril in moderate to severe HF [15,16].”
Background2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 67
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
Mohebi, R., Liu, Y., Piña, I. L., PRESCOTT, M. F., Butler, J., Felker, G. M., Ward, J. H., Solomon, S. D., & Januzzi, J. L. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.737 · Cited by 55
Self-citationKozaily, E., Geagea, M., Akdogan, R. E., Atkins, J., Elshazly, M. B., Guglin, M. E., Tedford, R. J., & Wehbe, R. M. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132115 · Cited by 59
Critical insights into the beneficial and protective actions of the kallikrein–kinin system
Regoli, D. C., & Gobeil, F. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2014.12.003 · Cited by 52
Plasma Corin as a Predictor of Cardiovascular Events in Patients With Chronic Heart Failure
Zhou, X., Chen, J.-C., Liu, Y., Yang, H., Du, K., Kong, Y., & Xu, X. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.03.006 · Cited by 46
Nadruz, W., Claggett, B. L., McMurray, J. J. V., Packer, M., Zile, M. R., Rouleau, J. L., Desai, A. S., Swedberg, K. B., Lefkowitz, M. P., Shi, V. C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024976 · Cited by 48
Self-citationKyoto Congestive Heart Failure (KCHF) Study: Rationale and Design
Yamamoto, E., Kato, T., Ozasa, N., Yaku, H., Inuzuka, Y., Tamaki, Y., Kitai, T., Morimoto, T., Taniguchi, R., Iguchi, M., et al. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12138 · Cited by 48
Lessons Learned in Acute Heart Failure
Cheema, B. S., Ambrosy, A. P., Kaplan, R. M., Senni, M., Fonarow, G. C., Chioncel, O. D., Butler, J., & Gheorghiade, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1042 · Cited by 50
Seki, T., Gotō, K., Kansui, Y., Ohtsubo, T., Matsumura, K., & Kitazono, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006617 · Cited by 46
Bouali, Y., Donal, E., Gallard, A., Laurin, C., Hubert, A., Bidaut, A., Leclercq, C., & Galli, E. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.031 · Cited by 50
Heart failure management in dialysis patients: Many treatment options with no clear evidence
Roehm, B. A., Gulati, G., & Weiner, D. E. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12878 · Cited by 52
Chaumais, M., Djessas, M. R. A., Thuillet, R., Cumont, A., Tu, L., Hebert, G., Gaignard, P., Huertas, A., Savale, L., Humbert, M. J. C., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa200 · Cited by 46
Morales, E., Cravedi, P., & Manrique, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.653634 · Cited by 56
“Nevertheless, side effects limit their use, particularly associated to diuretics (39), dual blockade of RAAS [“Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial,” ONTARGET (40), or “Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints,” ALTITUDE] (41, 42), or neprylisin inhibit…”
BackgroundPrognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis
Buchan, T. A., Ching, C., Foroutan, F., Malik, A., Daza, J. F., Hing, N. N. F., Siemieniuk, R. A. C., Evaniew, N., Orchanian‐Cheff, A., Ross, H. J., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10136-3 · Cited by 48
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
McMurray, J. J. V., Solomon, S. D., Docherty, K. F., & Jhund, P. S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz916 · Cited by 49
“12 As with dapagliflozin, a neprilysin inhibitor was beneficial even when added to an ACEi or ARB, beta-blocker, and an MRA.”
BackgroundSelf-citationBrain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure
Alcidi, G., Goffredo, G., Correale, M., Brunetti, N. D., & Iacoviello, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113192 · Cited by 51
“The possibility of using BNP as an HF therapy has been evaluated, either by administering a recombinant BNP peptide [6] or by inhibiting its degradation [7,8].”
MethodBrandt, M., Doerschmann, H., Khraisat, S., Knopp, T., Ringen, J., Kalinovic, S., Garlapati, V. S., Siemer, S., Molitor, M., Göbel, S., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18935 · Cited by 49
Consensus statement on the current pharmacological prevention and management of heart failure
Sindone, A. P., Pasquale, C. G. D., Amerena, J. V., Burdeniuk, C., Chan, A., Coats, A. J. S., Hare, D. L., Macdonald, P. S., Sverdlov, A. L., & Atherton, J. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51656 · Cited by 48
Financial Toxicity of Medical Management of Heart Failure
Sukumar, S., Wasfy, J. H., Januzzi, J. L., Peppercorn, J. M., Chino, F. L., & Warraich, H. J. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.402 · Cited by 47
Khallaf, W. A. I., Sharata, E. E., Attya, M. E., Abo‐Youssef, A. M., & Hemeida, R. A. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121789 · Cited by 46
Angioedema induced by cardiovascular drugs: new players join old friends
Baş, M., Greve, J., Straßen, U., Khosravani, F., Hoffmann, T. K., & Kojda, G. (2015) · Allergy · doi:10.1111/all.12680 · Cited by 50
“Recently, the results of the large PARADIGM-HF trial demonstrated that a combination of valsartan with the newly developed neprilysin inhibitor sacubitril (termed LCZ696) was superior to enalapril in patients with mild-to-moderate chronic heart failure with low left ventricular ejection fraction (35).”
ResultMolecular Screen Identifies Cardiac Myosin–Binding Protein-C as a Protein Kinase G-Iα Substrate
Thoonen, R., Giovanni, S., Govindan, S., Lee, D. I., Wang, G.-R., Calamaras, T. D., Takimoto, E., Kass, D. A., Sadayappan, S., & Blanton, R. M. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002308 · Cited by 46
Sacubitril/valsartan in heart failure: latest evidence and place in therapy
Kaplinsky, E. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316665350 · Cited by 53
“Renal function declination was defined as end-stage renal disease or a decrease ⩾50% in the estimated glomerular filtration rate form the randomization value or a decrease >30 ml/min per 1.73 m2, to <60 ml/min per 1.73 m2 [McMurray et al. 2014].”
BackgroundInfluentialCardiac rehabilitation in patients with pacemakers and implantable cardioverter defibrillators
Iliou, M. C., Blanchard, J. C., Tanguy, A. L., Cristofini, P., & Ledru, F. (2016) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2016.756 · Cited by 53
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Mogensen, U. M., Køber, L., Kristensen, S. L., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K. B., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.034 · Cited by 51
“The design and results of PARADIGM-HF have been published.(13-15) Briefly, PARADIGM-HF was a randomized, double-blind, and prospective comparison of the ARNI sacubitril/valsartan with enalapril in patients with chronic HF-REF.”
Self-citationLuo, N., Teng, T. K., Tay, W. T., Anand, I. S., Kraus, W. E., Liew, H. B., Ling, L. H., O’Connor, C. M., Piña, I. L., Richards, M., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.06.016 · Cited by 51
Kapelios, C. J., Lainščak, M., Savarese, G., Laroche, C., Seferovic, P. M., Ruschitzka, F. T., Coats, A. J. S., Anker, S. D., Crespo-Leiro, M. G., Filippatos, G. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1532 · Cited by 50
Jorba, G., Aguirre‐Plans, J., Junet, V., Segú-Vergés, C., Ruiz, J. L., Pujol, A., Fernández‐Fuentes, N., Mas, J. M., & Oliva, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228926 · Cited by 53
“During the clinical trials PARADIGM-HF and PARAGON-HF with sacubitril/valsartan no serious effects were detected [14,22].”
BackgroundMethodBilgen, F., Chen, P., Poggi, A., Wells, J., Trumble, E., Helmke, S., Teruya, S., Catalan, T., Rosenblum, H. R., Cornellier, M. L., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.04.004 · Cited by 45
Moon, M.-G., Hwang, I., Choi, W., Cho, G., Yoon, Y. E., Park, J., Lee, S., Kim, H., & Kim, Y.-J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13285 · Cited by 48
Remote Patient Monitoring in Heart Failure: Factors for Clinical Efficacy
Bhatia, A., & Maddox, T. M. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0023 · Cited by 58
Senni, M., Alemayehu, W. G., Sim, D., Edelmann, F., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2608 · Cited by 54
Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy
Liu, W., Zhang, X., Jiang, X., Dai, B., Zhang, L., & Zhu, Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.015 · Cited by 43
“Drugs including angiotensin receptor-neurolysin inhibitors, β -blockers, angiotensin-converting enzyme inhibitors, and mineralocorticoid-receptor antagonists reduce the influence of the mechanical drives for HF, but do not eliminate the latter [18 – 20].”
BackgroundFrom comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress
Franssen, C., Chen, H. S., Hamdani, N., & Paulus, W. J. (2015) · Heart · doi:10.1136/heartjnl-2015-307787 · Cited by 50
Cannon, M. V., Silljé, H. H. W., Sijbesma, J. W. A., Khan, M. A. F., Steffensen, K. R., van Gilst, W. H., & de Boer, R. A. (2016) · Diabetologia · doi:10.1007/s00125-015-3827-x · Cited by 44
“Interestingly, the recently published PARADIGM study [39] demonstrated the beneficial”
BackgroundAyalasomayajula, S. P., Langenickel, T., Jordaan, P., Zhou, W., Chandra, P., Albrecht, D., Pal, P., Rajman, I., & Sunkara, G. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2072-7 · Cited by 44
2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important?
Jessup, M. L., Marwick, T. H., Ponikowski, P. P., Voors, A. A., & Yancy, C. W. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.134 · Cited by 45
Wolff, G., Lin, Y., Karathanos, A., Brockmeyer, M., Wolters, S., Nowak, B., Fürnkranz, A., Makimoto, H., Kelm, M., & Schulze, V. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1079-0 · Cited by 45
“New pharmacologic treatments such as angiotensin receptor neprilysin inhibitors (ARNI [34]) and funny channel inhibitors [35, 36] have shown promising results in recent trials and have subsequently received guideline support [13], but have not found their way into ICD studies yet and thus were not part of the current…”
BackgroundSchoenfeld, H. A., West, T., Verghese, P. B., Holubasch, M. S., Shenoy, N., Kagan, D., Buono, C., Zhou, W., DeCristofaro, M. F., Douville, J., et al. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.03.014 · Cited by 48
Anzueto, A., Vogelmeier, C. F., Κostikas, Κ., Mezzi, K., Fucile, S., Bader, G., Shen, S., Banerji, D. D., & Fogel, R. (2017) · International Journal of COPD · doi:10.2147/copd.s133307 · Cited by 45
Packer, M., Pitt, B., Rouleau, J. L., Swedberg, K. B., DeMets, D. L., & Fisher, L. D. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.03.003 · Cited by 47
Self-citationSacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
Dargad, R. R., Prajapati, M. R., Dargad Rohit, R., & Parekh, J. D. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.01.002 · Cited by 52
“Notably, though sacubitrilat crosses blood–brain barrier (BBB), no corresponding increase in amyloid-β levels or amyloid-β accumulation were noted in the brain tissues of cynomolgus monkeys.(7,18)”
BackgroundResultChang, H. Y., Wang, C. C., Wu, Y., Chu, P. H., Wu, C., Hsu, C., Wen, M.-S., Voon, W., Lin, W. S., Huang, J. L., et al. (2017) · PubMed · doi:10.6515/acs20170202a · Cited by 50
Lam, P. H., Packer, M., Fonarow, G. C., Faselis, C. J., Allman, R. M., Morgan, C. J., Singh, S. N., Pitt, B., & Ahmed, A. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.06.053 · Cited by 49
Self-citationKahles, F., Rückbeil, M. V., Mertens, R. W., Foldenauer, A. C., Arrivas, M. C., Moellmann, J., Lebherz, C., Biener, M., Giannitsis, E., Katus, H. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz728 · Cited by 44
LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress
Xu, S., Wang, Y., Yu, M., Wang, D., Liang, Y., Chen, Y., Liao, C., Xie, Z., Zhao, B., Han, J., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109803 · Cited by 44
Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
Greenberg, B. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0002 · Cited by 55
Kanagala, P., Arnold, J. R., Singh, A., Chan, D. C. S., Cheng, A. S. H., Khan, J. N., Gulsin, G. S., Yang, J., Zhao, L., Gupta, P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232280 · Cited by 50
“As the HFrEF cohort were age and sex-matched to the HFpEF population and were not consecutively enrolled, they may not be representative of the general population with HFrEF, albeit similar in demographics to recent large phase III clinical HFrEF trials as reported above[58, 59].”
ResultSuzuki, K., Claggett, B. L., Minamisawa, M., Nochioka, K., Mitchell, G. F., Anand, I. S., Zannad, F. M., Shah, S. J., Lefkowitz, M. P., Shi, V. C., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16277 · Cited by 47
Self-citationSex-related differences in the pharmacological treatment of heart failure
Tamargo, J. L., Caballero, R., & Delpón, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107891 · Cited by 46
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Tsutsui, H. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108185 · Cited by 47
Chen, Y., Harris, S. K., Rogers, Y., Ahmad, T., & Asselbergs, F. W. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac030 · Cited by 48
“McMurray et al.(22) Sacubitril/valsartan novel drug in patients”
Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy
Bai, Y., Zhang, X., Li, Y., Qi, F., Liu, C., Ai, X., Tang, M., Szeto, C. W., Gao, E., Hua, X., et al. (2024) · Circulation Research · doi:10.1161/circresaha.123.322729 · Cited by 46
“Survival rate difference was determined by Kaplan-Meier survival analysis in PKA Is Essential for Cardiac Growth failure treatment taking advantage of the increased ANP in the blood by neprilysin inhibitor, 43 and it also reduced CH in hypertensive patients.”
MethodThe double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
“…(ARBs) [118], β-blockers [119, 120], mineralocorticoid receptor antagonists (MRAs) [121, 122], and, more recently sacu-bitril/valsartan (a neprilysin inhibitor/ARBs) [123] and ivabradine [124] have all resulted in significant reductions in CV events in terms of mortality and hospitalizations.”
BackgroundObesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 56
“17,19 20 – 22 Obesity increases CV mortality and predisposes progression towards HF. 23 As a matter of fact, obesity can be considered the perfect storm for CV disease, representing a leading cause of HF.”
BackgroundInfluentialCARDIOVASCULAR DISEASE, SIGNALING, GENE/CELL THERAPY AND ADVANCED NANOBIOMATERIALS
Erdil, N. (2024) · Advances in Biology & Earth Sciences · doi:10.62476/abes9s58 · Cited by 44
LCZ 696 (Valsartan/Sacubitril) – A Possible New Treatment for Hypertension and Heart Failure
Andersen, M. B., Simonsen, U., Wehland, M., Pietsch, J., & Grimm, D. G. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12453 · Cited by 50
Synthesis of a Precursor to Sacubitril Using Enabling Technologies
Lau, S., Bourne, S. L., Martin, B. R., Schenkel, B., Penn, G., & Ley, S. V. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b02806 · Cited by 44
Global cardiovascular protection in chronic kidney disease
Ruiz‐Hurtado, G., Sarafidis, P. A., Fernández‐Alfonso, M. S., Waeber, B., & Ruilope, L. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.48 · Cited by 45
Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure
Lainščak, M., Vitale, C., Seferovic, P. M., Spoletini, I., Trobec, K. Č., & Rosano, G. M. C. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.015 · Cited by 45
Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension
Supasyndh, O., Sun, N., Kario, K., Hafeez, K., & Zhang, J. Y. (2016) · Hypertension Research · doi:10.1038/hr.2016.151 · Cited by 43
Levinsson, A., Dubé, M., Tardif, J., & de Denus, S. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12307 · Cited by 45
Al‐Gobari, M., Al-Aqeel, S., Gueyffier, F., & Burnand, B. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021108 · Cited by 46
“The authors acknowledged the limitation of their meta-analysis, which was not based on a systematic review, but merely pooling three well-known trials published in high impact journals (ie, IMPRESS,(61) OVERTURE(62) and PARADIGM-HF).(5) The quality of the evidence is, however, moderate for SCD and high for all-cause m…”
BackgroundResultInfluentialChronic heart failure: a disease of the brain
Singh, R. B., Hristová, K., Fedačko, J., Elkilany, G. E. N., & Cornélissen, G. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9747-3 · Cited by 43
Patient Perceptions and Familiarity With Medical Therapy for Heart Failure
Samsky, M. D., Li, L., Greene, S. J., Lippmann, S., Peterson, P. N., Heidenreich, P. A., Laskey, W. K., Yancy, C. W., Greiner, M. A., Hardy, N. C., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4987 · Cited by 43
Chakravarty, T., Henry, T. D., Kittleson, M. M., Lima, J. A. C., Siegel, R. J., Slipczuk, L. N., Pogoda, J. M., Smith, R. R., Malliaras, K. G., Marbán, L., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-19-00035 · Cited by 43
Current status of heart failure: global and Korea
Park, J. J., & Choi, D. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.120 · Cited by 47
“The proportion of patients with the diagnosis of HFpEF defined as LVEF > 50% increased over time, whereas that of HFrEF did not change significantly over time [16].”
BackgroundInfluentialKoshikawa, M., Harada, M., Noyama, S., Kiyono, K., Motoike, Y., Nomura, Y., Nishimura, A., Izawa, H., Watanabe, E., & Ozaki, Y. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01514-0 · Cited by 52
Role of Kinins in Hypertension and Heart Failure
Hamid, S., Rhaleb, I. A., Kassem, K. M., & Rhaleb, N. (2020) · Pharmaceuticals · doi:10.3390/ph13110347 · Cited by 44
Machine learning and statistical methods for predicting mortality in heart failure
Mpanya, D., Çelik, T., Klug, E., & Ntsinjana, H. N. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10052-y · Cited by 48
Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?
Zhu, D., & Cheng, K. (2021) · Cells · doi:10.3390/cells10030641 · Cited by 49
Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
Gager, G. M., Gelbenegger, G., Jilma, B., von Lewinski, D., Sourij, H., Eyileten, C., Filipiak, K. J., Postula, M. A., & Siller-Matula, J. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.691907 · Cited by 50
“(35) EMPERIAL-Reduced Empagliflozin 10mg once daily Placebo Double-blind RCT 312 312 (100) HFrEF 187 (60) 12 weeks 69”
MethodLiu, J., Zheng, X., Zhang, C., Zhang, C., & Bu, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724147 · Cited by 43
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.